Trials / Active Not Recruiting
Active Not RecruitingNCT05119907
Study of Sacituzumab Govitecan in Patients With Solid Tumor
A Phase II Open Label Study of Sacituzumab Govitecan in Patients With Solid Tumor
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to see how effective the study drug, sacituzumab govitecan-hziy, is in participants with solid tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sacituzumab Govitecan-hziy | Administered intravenously |
Timeline
- Start date
- 2021-10-12
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2021-11-15
- Last updated
- 2025-11-17
Locations
13 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05119907. Inclusion in this directory is not an endorsement.